PMID: 2504619Jul 1, 1989Paper

In vitro and in vivo characterization of a high-purity, solvent/detergent-treated factor VIII concentrate: evidence for its therapeutic efficacy in von Willebrand's disease

European Journal of Haematology
C MazurierM Goudemand

Abstract

A factor VIII (FVIII) concentrate, virus-inactivated by the solvent/detergent procedure, was studied in vitro. In contrast with most high-purity, virus-inactivated FVIII concentrates, it contains not only high levels of von Willebrand factor (vWF) antigen and ristocetin cofactor activity but also high molecular weight forms of von Willebrand factor. Furthermore, it is able to promote platelet adhesion on collagen in a perfusion system. In vivo studies performed in patients with different types of von Willebrand's disease provided evidence that this concentrate corrects Duke's bleeding time and prevents or stops haemorrhages. Thus, the particular advantages of this FVIII/vWF preparation are safety, low content of contamination proteins, and efficacy in von Willebrand's disease.

References

Mar 1, 1988·European Journal of Haematology·E Berntorp, I M Nilsson
Apr 1, 1983·Revue française de transfusion et immuno-hématologie·A LefèvreM Goudemand
Jan 1, 1955·British Journal of Haematology·R BIGGSG RICHARDS

❮ Previous
Next ❯

Citations

Apr 17, 2004·Haemophilia : the Official Journal of the World Federation of Hemophilia·K J PasiI R Peake
Mar 1, 1993·Indian Journal of Pediatrics·I M Nilsson, S Lethagen
Mar 17, 2004·Vox Sanguinis·C MazurierS Chtourou
Mar 10, 2001·Haemophilia : the Official Journal of the World Federation of Hemophilia·W K Hoots
Mar 1, 1992·European Journal of Haematology·L Holmberg, I M Nilsson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.